Our Board

Neil Roskell

Neil Roskell

Chief Practice Officer: Modelling and Analytics

Neil joined BresMed as Head of Statistics in January 2014, with the remit to support statistical input to health technology assessment (HTA) and health economics activities, and to grow the Statistics team. Before joining BresMed, Neil established and led the Evidence Review and HTA Analysis team at RTI Health Solutions for 9 years. Neil worked for GSK as a Phase II-IV clinical trial statistician from 1996–2004. Throughout his career, Neil has contributed to, and taken responsibility for, statistical input to successful submissions to regulatory agencies and HTA agencies in the US, EU, UK, Canada, Germany and Australia. Neil enjoys a healthy balance between business responsibility, people management, client interactions and appropriate statistical consultancy.

Neil holds a Masters degree in Medical Statistics from the London School of Hygiene and Tropical Medicine and a Bachelors degree in Mathematics and Statistics from the University of Newcastle-upon-Tyne.

In his spare time Neil enjoys playing (trying to play) golf, watching Liverpool FC, going to gigs, trying to get a word in edgeways with his three children, and relaxing with his wife.

What Neil says about BresMed: “There is a real commitment and ambition to always ‘partner with’ rather than ‘serve’ our clients. BresMed is a unique consultancy with a tangible vibrancy in the teams; highly qualified, skilled and motivated research staff, and a great sense of team spirit and fun. As BresMed continues to thrive and grow, these attributes will be core to the company’s ethos and principles. It is a pleasure to work with so many people who amaze me and who I learn from every day. My biggest work achievements have been watching colleagues and team members flourish.”

Curriculum vitae

Employment history

2021-Present   Chief Practice Officer, Modelling and Analytics  BresMed

2014-2021   Business Unit Head/Vice President, Statistics   BresMed

2013-2013   Consultant Statistician   CROS NT

2004-2013   Head of Evidence Review and HTA Analyses   RTI Health Solutions

2003-2004   Statistician, Epidemiology   GSK

1996-2003   Clinical Trial Statistician/Project Statistician   GSK

1995-1996   Statistician in Pre-Clinical Statistics   Corning Hazelton (now Covance)

 

Research interests

Current research areas include:

  • All forms of indirect treatment comparisons
  • Parametric survival analyses
  • Appropriate statistical consulting – in particular, understanding and clarifying the question before reaching for solutions, and not overselling complex statistical solutions on limited data

 

Therapeutic areas of expertise

Cardiovascular and metabolic disorders (including diabetes)

  • Atrial fibrillation – Led a network meta-analysis using frequentist and Bayesian methods, comparing a new oral anticoagulant with existing treatments, resulting in a publication and use in HTA submissions. Led a systematic review of major bleeding rates with warfarin use in randomized controlled trials and observational studies (for publication)
  • Venous thromboembolism – Led an analysis of clinical trial data to summarize resource use and cost information
  • Heart failure with reduced ejection fraction – Input into the design and conduct of matching-adjusted indirect treatment comparisons
  • Diabetes – Led a systematic review and a network meta-analysis studying sodium/glucose cotransporter 2 (SGLT2) inhibitors, glucagon-like peptide-1 (GLP1) agonists, dipeptidyl peptidase-4 (DPP4) inhibitors and insulin

 

Central nervous system

  • Dravet syndrome (epilepsy in infants/children) – Led a suite of indirect treatment comparisons to support orphan designation and breakthrough therapy status
  • Epilepsy – Led a project including indirect treatment comparisons, matching-adjusted indirect treatment comparisons, systematic literature review and network meta-analyses
  • Migraine – Led a project to plan and perform indirect treatment comparisons using matching-adjusted indirect comparisons methods

 

Dermatology

  • Psoriasis – Led a project to plan and report a large network meta-analysis

 

Gastrointestinal

  • Intestinal failure – Led hospital database analyses to link parenteral nutrition to clinical outcomes

 

Haematology (including blood cancers)

  • Haemophilia – Performed indirect treatment comparisons and modelling to predict treatment effects over time for bleeding events

 

Infectious diseases

  • Hepatitis C – Performed a systematic review and network-meta analysis for use in economic models, HTA submissions and a publication
  • Human immunodeficiency virus (HIV) – Clinical trial statistician, including input into four regulatory submissions (two for the US Food and Drug Administration [FDA] and two European)
  • Malaria – International project statistician, leading a compound from Phase II through submission and into Phase IV. Input into protocols, wrote statistical analysis plans, and performed/reported clinical trial analyses

 

Inflammation and immunology

  • Multiple sclerosis – Led a network meta-analysis of an oral disease-modifying therapy (DMT) versus existing DMTs for publication and use in an economic model and HTA submissions. Expanded the network meta-analysis to incorporate emerging therapies

 

Musculoskeletal & joints diseases

  • Fibromyalgia – Led a network meta-analysis for use in a publication and an economic model, comparing a serotonin–norepinephrine reuptake inhibitor with other licensed and unlicensed treatments

 

Oncology

  • Breast cancer – Multiple methods for parametric survival analyses and indirect treatment comparisons
  • Hepatocellular carcinoma – Multiple methods for parametric survival analyses and matching-adjusted indirect comparisons
  • Leukaemia – Multiple methods for parametric survival analyses
  • Melanoma – Multiple methods for parametric survival analyses and indirect treatment comparisons
  • Multiple myeloma – Multiple methods for parametric survival analyses and matching-adjusted indirect comparisons (and other forms of indirect treatment comparisons)
  • Myelofibrosis – Led an analysis of clinical trial data to map European Organisation for Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire (QLQ)-C30 responses to utility using different algorithms. Included comparisons by treatment and by health state
  • Non-Hodgkin lymphoma – Multiple methods for parametric survival analyses and matching-adjusted indirect comparisons
  • Non-small-cell lung cancer – Multiple methods for parametric survival analyses, utility analyses, and indirect treatment comparisons
  • Prostate cancer – Multiple methods for parametric survival analyses and indirect treatment comparisons
  • Thyroid cancer – Multiple methods for parametric survival analyses and indirect treatment comparisons

 

Ophthalmology

  • Age-related macular degeneration – Performed parametric survival modelling to provide inputs to an economic model and subsequent HTA submission
  • Diabetic macular oedema – Contributed to the statistical elements of a National Institute for Health and Care Excellence (NICE) submission, including a network meta-analysis
  • Glaucoma – Led an analysis of an observational database to understand treatment patterns and persistence (leading to a publication)

 

Psychiatric conditions (including alcohol and substance dependence)

  • Attention deficit hyperactivity disorder (ADHD) – Led a network meta-analysis for inclusion in an economic model and for publication
  • Bipolar disorder – Led a project to plan and report a large network meta-analysis
  • Post-partum depression – Led a project to plan and report indirect treatment comparisons using network meta-analysis and matching-adjusted indirect comparisons methods
  • Schizophrenia – Led a project to plan and report a large network meta-analysis
  • Suicide (in patients receiving antidepressants) – Performed an observational database (Clinical Practice Research Datalink [CPRD]) analysis of risk of suicide with antidepressants

 

Respiratory

  • Chronic obstructive pulmonary disease (COPD) – Led a systematic review and a network meta-analysis (for publication) studying new, once-daily, long-acting, β-agonist treatments. Led a CPRD database study of using bronchodilators as monotherapy and in combination in the UK. Led a systematic review and network meta-analysis comparing all long-acting, muscarinic antagonist treatments
By continuing to browse or by clicking "Accept All Cookies" you agree to the storing of first and third-party cookies on your device to enhance site navigation, analyze site usage, and assist in our marketing efforts.
Cookie Policy
Accept All Cookies
By continuing to browse or by clicking "Accept All Cookies" you agree to the storing of first and third-party cookies on your device to enhance site navigation, analyze site usage, and assist in our marketing efforts.
Cookie Policy
Accept All Cookies